Jivi® is the EHL rFVIII that offers unique step-wise prophylaxis dosing1,2

Study Design Chart
8/10
patients in PROTECT VIII reduced dosing frequency vs. their pre-study prophylaxis regimen3†
  • 100% of patients in the every 5 days and twice weekly dosing arms remained on the same dosing regimen for the duration of the main study.1
  • n=40/47 patients in the every 5 days and twice weekly dosing arms for whom prior prophylaxis dosing records were available.3
  • EHL, extended half-life; rFVIII, recombinant Factor VIII.